Upon the approval of State Food and Drug Administration, Sanhuangsan, a novel compound made up of 16 Chinese traditional herbs, has been allowed into clinical trials.
Since 2000, a number of research institutes, including Yunnan Key Lab for Natural Medicines, the Kunming Institute of Zoology, a part of the Chinese Academy of Sciences, and the Institute of Biotechnology under the Chinese Academy of Medical Sciences, have worked on pre-phase studies of toxicant, pharmaceutical and therapeutic aspects of the new drug. The test results show that the drug is able to blockade virus duplications in affected cells, through effectively inhibiting HIV-1 IN. The results of an experiment on the immunity impacts on rats with weakened immunity show that it effectively improves 5 immunity indicators concerning AIDS diseases, with one of them reaches and four of them exceed the comparison groups. The therapeutic results on treating some 100 domestic and overseas AIDS patients on a trial basis show that long term taking of the medicine produces no toxicant or adverse effects, subjectively or objectively. The treated patients saw a gradual decrease of AIDS viruses, and witnessed no rebound after ceasing to take the medicine. Patients enjoyed an apparent remission after the treatment with the drug. |
